SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first two patients have been dosed in the U.S.

The partnership brings together the strengths of an innovative global biotech and a domestic leading pharmaceutical company specialized in and committed to pediatric medicines to accelerate the commercialization of eftansomatropin alfa Jumpcan will pay I-Mab for a total of up to RMB 2.016 billion

Preclinical d ata of TJ-CD4B/ABL111 and TJ-L14B/ABL503   demonstrate targeted safety profile and enhanced anti-tumor activity Both studies are undergoing phase 1 clinical trials in the United States SHANGHAI and GAITHERSBURG, Md. and SEONGNAM, South Korea , Nov.

SHANGHAI and GAITHERSBURG, Md. , Nov. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Company has entered into a strategic

Lemzoparlimab is a differentiated CD47 monoclonal antibody discovered by I-Mab and being developed in collaboration with AbbVie Initial clinical results of lemzoparlimab in combination with rituximab in NHL will be presented at the ASH 2021 Annual Meeting I-Mab to host a call for investors on

SHANGHAI and GAITHERSBURG, Md. , Nov. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced its participation in the following conferences in

- Industry veteran John Long appointed as CFO to lead I-Mab's global corporate finance and capital market activities - Jielun Zhu named as CSO to focus on corporate strategy, strategic partnerships and transactions, and corporate ventures - The new appointments bring significant global

I-Mab strategic partnership with Sinopharm will covers all aspects of the go-to-market process, including authorization of more than 300 Sinopharm's subsidiaries as distributors across China . I-Mab is on track to submit BLA for third line multiple myeloma (MM) treatment by Q4 2021.

-  I-Mab will strengthen its global R&D presence, with a new world-class R&D and operational site, located in the heart of the rapidly growing San Diego biotech hub -  The new site will complement I-Mab's   Global Clinical Development site in Gaithersburg, Maryland to form an integrated I-Mab US

SHANGHAI and GAITHERSBURG, Md. , Oct. 18, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China